What evidence shows Ebglyss (lebrikizumab) works for moderate-to-severe atopic dermatitis?
Ebglyss (lebrikizumab) is an anti-IL-13 monoclonal antibody studied in phase 2/3 trials that enrolled people with moderate-to-severe atopic dermatitis. In these studies, many patients reached clear or almost clear skin and improved itch compared with placebo, including sustained responses over time. The strength of benefit is typically reported using measures such as EASI-75 (75% improvement in Eczema Area and Severity Index), EASI-90, and itch outcomes.
How much skin improvement do patients typically see?
For moderate-to-severe atopic dermatitis, trials evaluate how many people achieve clinically meaningful eczema improvement (most commonly EASI-75). In lebrikizumab studies, a substantial share of participants reached EASI-75, and higher proportions achieved EASI-90 or greater skin clearance versus placebo. These responder rates are the main way effectiveness is quantified for this population.
How fast does itch and eczema improve?
Atopic dermatitis effectiveness is assessed not only by skin scores but also by itch (often measured using patient-reported pruritus scales). In the lebrikizumab trials, itch and eczema severity improved over the course of treatment, with benefits typically appearing after early dosing and continuing to build or remain improved through later time points used in study reporting.
Is Ebglyss effective for people who failed other treatments?
Moderate-to-severe atopic dermatitis populations often include patients with prior systemic therapy and/or inadequate response to earlier treatments. In trial settings for lebrikizumab, participants still showed meaningful response on key endpoints compared with placebo, which supports effectiveness across a broader moderate-to-severe group rather than only treatment-naïve patients.
What about safety and tolerability alongside effectiveness?
Effectiveness is usually interpreted together with adverse events rates reported in the pivotal studies. Across anti-cytokine atopic dermatitis programs, common concerns include injection-site reactions and infection risk signals consistent with immune-modulating therapy. Any decision to use Ebglyss generally depends on balancing these risks against how strongly a patient responds on eczema clearance and itch reduction endpoints.
How to check exact trial results for “moderate-to-severe” and your specific situation
If you want the most precise effectiveness numbers (for example, exact EASI-75/EASI-90 percentages, itch score changes, and how long responses lasted), those details are best confirmed in the product’s approved label and/or the registration trial publications. DrugPatentWatch.com can also help track development and regulatory details for Ebglyss, including relevant filings and timelines: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/